Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Liang, Yin ^a   Arakawa, Kenji ^b   Ueta, Kiichiro ^b   Matsushita, Yasuaki ^b   Kuriyama, Chiaki ^b   Martin, Tonya ^a   Du, Fuyong ^a   Liu, Yi ^a   Xu, June ^a   Conway, Bruce ^a   Conway, Jamie ^a   Polidori, David ^a   Ways, Kirk ^a   Demarest, Keith ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA METHYLGLUCOSIDE; CANAGLIFLOZIN; CARBON 14; DEOXYGLUCOSE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; TRITIUM; 1 (GLUCOPYRANOSYL) 4 METHYL 3 (5 (4 FLUOROPHENYL) 2 THIENYLMETHYL)BENZENE; 1-(GLUCOPYRANOSYL)-4-METHYL-3-(5-(4-FLUOROPHENYL)-2-THIENYLMETHYL)BENZENE; GLUCOSIDE; SGLT2 PROTEIN, RAT; SLC5A1 PROTEIN, RAT; SLC5A4 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER; THIOPHENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CHO CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EPIDIDYMIS FAT; GLUCOSE BLOOD LEVEL; GLUCOSURIA; IN VITRO STUDY; INSULIN RELEASE; LIVER WEIGHT; LUNG GAS EXCHANGE; MALE; MOUSE; MYOBLAST; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OOCYTE; PROTEIN EXPRESSION; RAT; RENAL SYSTEM PARAMETERS; SINGLE DRUG DOSE; TREATMENT DURATION; URINARY EXCRETION; VOLTAGE CLAMP; WEIGHT GAIN; ANIMAL; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DRUG ANTAGONISM; EXPERIMENTAL DIABETES MELLITUS; GENETICS; GLUCOSE TOLERANCE TEST; HAMSTER; HUMAN; HYPERGLYCEMIA; KIDNEY; METABOLISM; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; SKELETAL MUSCLE; ZUCKER RAT;

ANIMALIA; CRICETULUS GRISEUS; MUS; RATTUS; RODENTIA;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CELLS, CULTURED; CHO CELLS; CRICETINAE; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE TOLERANCE TEST; GLUCOSIDES; HUMANS; HYPERGLYCEMIA; KIDNEY; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; MUSCLE, SKELETAL; RATS; RATS, ZUCKER; SODIUM-GLUCOSE TRANSPORT PROTEINS; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES; WEIGHT GAIN;

EID: 84857099986     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0030555     Document Type: Article

References (43)

1. Wild S, Roglic G, Green A, Sicree R, King H, (2004) Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053.
2. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB, (2008) Is glycemic control improving in U.S. adults? Diabetes Care 31: 81-86.
3. Wright EM, Hirayama BA, Loo DF, (2007) Active sugar transport in health and disease. J Intern Med 261: 32-43.
4. Wright EM, Turk E, (2004) The sodium/glucose cotransport family SLC5. Pflügers Arch- Eur J Physiol 447: 510-518.
5. Kloeckener-Gruissem B, Vandekerckhove K, Nürnberg G, Neidhardt J, Zeitz C, et al. (2008) Mutation of solute carrier SLC16A12 associates with a syndrome combining juvenile cataract with microcornea and renal glucosuria. Am J Hum Genet 82: 772-779.
6. Santer R, Calado J, (2010) Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 5: 133-141.
7. Wright EM, (1998) Genetic disorders of membrane transport: I. Glucose galactose malabsorption. Am J Physiol Gastrointest Liver Physiol 275: G879-G882.
8. Vallon V, Platt KA, Cunard R, Schroth J, Whaley J, et al. (2010) SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 22: 104-112.
9. Ehrenkranz JRL, Lewis NG, Kahn CR, Roth J, (2005) Phlorizin: a review. Diabetes Metab Res Rev 21: 31-38.
10. Rossetti L, Shulman GI, Zawalich W, DeFronzo RA, (1987) Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 80: 1037-1044.
11. Mather A, Pollock C, (2010) Renal glucose transporters: novel targets for hyperglycemia management. Nat Rev Nephrol 6: 307-311.
12. Nair S, Wilding J, (2010) Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 95: 34-42.
13. Bakris GL, Fonseca VA, Sharma K, Wright EM, (2009) Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 75: 1272-1277.
14. Chao EC, Henry RR, (2010) SGLT2 inhibition - a novel strategy for diabetes treatment. Nat Rev Drug Discov 9: 551-559.
15. Nomura S, Sakamaki S, Hongu M, Kawanishi E, Koga Y, et al. (2010) Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 53: 6355-6360.
16. Voss AA, Díez-Sampedro A, Hirayama BA, Loo DF, Wright EM, (2007) Imino sugars are potent agonists of the human glucose sensor SGLT3. Mol Pharmacol 71: 628-634.
17. Magni L, Raimondo DM, Bossi L, Man CD, De Nicolao G, et al. (2007) Model predictive control of type 1 diabetes: an in silico trial. J Diabetes Sci Technol 6: 804-12.
18. Sha S, Devineni D, Ghosh A, Polidori D, Chien S, et al. (2011) Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab 13: 669-672.
19. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, et al. (2011) Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors [published online ahead of print October 12, 2011] Diabetes Obes Metab doi: 10.1111/j.1463-1326.2011.01517.x.
20. Diez-Sampedro A, Hirayama BA, Osswald C, Gorboulev V, Baumgarten K, et al. (2003) A glucose sensor hiding in a family of transporters. Proc Natl Acad Sci USA 100: 11753-11758.
21. Nair S, Wilding J, (2010) Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 95: 34-42.
22. Rave K, Nosek L, Posner J, Heise T, Roggen K, et al. (2006) Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes-results of a hyperglycaemic glucose clamp study. Nephrol Dial Transplant 21: 2166-2171.
23. Vestri S, Okamoto MM, Freitas HS, dos Santos RA, Nunes MT, et al. (2001) Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J Membr Biol 182: 105-112.
24. Freitas HS, Anhê GF, Melo KFS, Okamoto MM, Oliveira-SouzaM, et al. (2008) Na(+)-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology 149: 717-724.
25. Kamran M, Peterson R, Dominguez J, (1997) Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats. J Am Soc Nephrol 8: 943-948.
26. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, et al. (2005) Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54: 3427-3434.
27. Mogensen CE, (1971) Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 28: 101-109.
28. Farber SJ, Berger EY, Earle DP, (1951) Effect of diabetes and insulin on the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 30: 125-129.
29. Arakawa K, Ishihara T, Oku A, Nawano M, Ueta K, et al. (2001) Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol 132: 578-586.
30. Nunoi K, Yasuda K, Adachi T, Okamoto Y, Shihara N, et al. (2002) Beneficial effect of T-1095, a selective inhibitor of renal Na+-glucose cotransporters, on metabolic index and insulin secretion in spontaneously diabetic GK rats. Clin Exp Pharmacol Physiol 29: 386-390.
31. Del Prato S, (2009) Role of glucotoxicity and lipotoxicity in the pathophysiology of type 2 diabetes mellitus and emerging treatment strategies. Diabetic Med 26: 1185-1192.
32. Eizirik DL, Cardozo AK, Cnop M, (2008) The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev 29: 42-61.
33. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, et al. (2003) Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52: 102-110.
34. Ueta K, Ishihara T, Matsumoto Y, Oku A, Nawano M, et al. (2005) Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki rats. Life Sci 76: 2655-2668.
35. Kahn SE, (2001) Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 86: 4047-4058.
36. Fujimori Y, Katsuno K, Ojima K, Nakashima I, Nakano S, et al. (2009) Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 609: 148-154.
37. Oku A, Ueta K, Nawano M, Arakawa K, Kano-Ishihara T, et al. (2000) Antidiabetic effect of T-1095, an inhibitor of Na(+)-glucose cotransporter, in neonatally streptozotocin-treated rats. Eur J Pharmacol 391: 183-192.
38. Jurczak MJ, Lee HY, Birkenfeld AL, Jornayvaz FR, Frederick DW, et al. (2011) SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes 60: 890-898.
39. Han S, Hagan DL, Taylor JR, Xin L, Meng W, et al. (2008) Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 57: 1723-1729.
40. Rosenstock J, Arbit D, Usiskin K, Capuano G, Canovatchel W, (2010) Canagliflozin, an inhibitor of sodium glucose co-transporter 2 (SGLT2), improves glycemic control and lowers body weight in subjects with type 2 diabetes on metformin. Diabetes 59: A78.
41. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, et al, (2009) A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 32: 1656-1662.
42. List JF, Woo V, Morales E, Tang W, Fiedorek FT, (2009) Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32: 650-657.
43. Bailey CJ, Gross JL, Pieters A, Bastien A, List J, (2010) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375: 2223-2233.